Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

تأخير الانتشار المحلي - 2/4/2020


                  
تأخير الانتشار المحلي 2/4/2020                                                                                  العدد الإجمالي للحالات الايجابية لفيروس التاجي المستجد 2/4/2020


         
 العدد الإجمالي للحالات الايجابية لفيروس التاجي المستجد 2/4/2020                          العدد اليومي والإجمالي للحالات الايجابية لفيروس التاجي المستجد 2/4/2020
 


The scale of 5000 is based on a realistic estimation of the capacity of the health care system.

If 5000 people are infected, about 20% would need hospital care (1000 patient), 5% would be admitted in intensive care units (250 patients), while 2-3% would need mechanical ventilation (150 patients).

Knowing that 5000 is a cumulative number starting Feb. 21as shown in figure 3. It is worth mentioning, that the 1000 patients are not expected to be all hospitalized at the same time. They will rather be progressively admitted and discharged over the considered period of time. Calculation done in terms of patient days shows that the demand generated by 5000 positive cases would remain compatible with the health system capacity.

The hospital capacity is expected to be 576 beds + 234 ICU beds + 263 ventilators, all dedicated to covid-19 patients, by April 1st 2020. Knowing that this capacity will gradually be enhanced (raising the bar of the figure 1).

Our strategy is to flatten the curve while increasing the capacity of the health care system to adequately respond to this pandemic.

Help us by following the instructions of the Ministry of Public Health and most of all STAY AT HOME.







































The scale of 5000 is based on a realistic estimation of the capacity of the health care system.
If 5000 people are infected, about 20% would need hospital care (1000 patient), 5% would be admitted in intensive care units (250 patients), while 2-3% would need mechanical ventilation (150 patients).
Knowing that 5000 is a cumulative number starting Feb. 21as shown in figure 3. It is worth mentioning, that the 1000 patients are not expected to be all hospitalized at the same time. They will rather be progressively admitted and discharged over the considered period of time. Calculation done in terms of patient days shows that the demand generated by 5000 positive cases would remain compatible with the health system capacity.
The hospital capacity is expected to be 576 beds + 234 ICU beds + 263 ventilators, all dedicated to covid-19 patients, by April 1st 2020. Knowing that this capacity will gradually be enhanced (raising the bar of the figure 1).

Our strategy is to flatten the curve while increasing the capacity of the health care system to adequately respond to this pandemic.

Help us by following the instructions of the Ministry of Public Health and most of all STAY AT HOME.
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BD02 BERIATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
J05AF10 HEPCAVIR 1 G Entecavir monohydrate - 1mg 1mg Tablet, film coated L.L
J05AF10 HEPCAVIR 0.5 G Entecavir monohydrate - 0.5mg 0.5mg Tablet, film coated L.L
B06AC05 TAKHZYRO BioTech Lanadelumab - 300mg/2ml 300mg Injectable solution L.L
N05AX13 TREVICTA B Paliperidone - 525mg 525mg Injectable suspension, prolonged release L.L
N05AX13 TREVICTA B Paliperidone - 350mg 350mg Injectable suspension, prolonged release L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 150mg 150mg Injectable suspension, prolonged release L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 100mg 100mg Injectable suspension, prolonged release L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg week 1, Venetoclax - 50mg week 2, Venetoclax - 100mg week 3&4 Tablet L.L
L04AC05 USTEKIREL BioTech Ustekinumab - 90mg 90mg Injectable solution L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 15mg 15mg Capsule L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 10mg 10mg Capsule L.L
L01CE02 IRINOTECAN GP PHARM G Irinotecan HCl trihydrate - 100mg/5ml 100mg/5ml Injectable concentrated solution L.L
L01XA03 OXALIPLATIN EBEWE G Oxaliplatin - 50mg/10ml 50mg/10ml Injectable concentrated solution L.L
L01CA04 EBERELBIN G Vinorelbine (tartrate) - 50mg/5ml 50mg/5ml Injectable concentrated solution L.L
L01BC01 ALEXAN G Cytarabine - 1,000mg/20ml 1,000mg/20ml Injectable solution L.L
L01CD02 DOCETAXEL EBEWE G Docetaxel - 80mg/8ml 80mg/8ml Injectable solution L.L
L04AA06 MYFORTIC B Mycophenolic acid (sodium) - 360mg 360mg Tablet, gastroresistant L.L
N03AF01 TEGRETOL B Carbamazepine - 2% 2% Suspension L.L
L01DB01 DOXORUBICINE EBEWE G Doxorubicin HCl - 2mg/ml 50mg/25ml Injectable concentrated solution L.L
L01CE02 IRINOTECAN THYMOORGAN G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable concentrated solution L.L
L01AA06 HOLOXAN B Ifosfamide - 1g 1g Injectable powder for solution L.L
L01AX03 TEGOZOL G Temozolomide - 250mg 250mg Capsule L.L
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 100mg 100mg Injectable lyophilised powder for solution L.L
L04AA44 RINVOQ B Upadacitinib - 15mg 15mg Tablet, prolonged release L.L
L01CD02 DOCETAXEL ACCORD G Docetaxel - 20mg/ml 20mg/1ml Injectable concentrate for solution L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution L.L
J05AB14 VALGANCICLOVIR ARROW G Valganciclovir (HCl) - 450mg 450mg Tablet, coated L.L
M05BX04 PROLIA BioTech Denosumab - 60mg/ml 60mg/ml Injectable solution L.L
B02BX06 HEMLIBRA BioTech Emicizumab - 150mg/ml 150mg/ml Injectable solution L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026